BioCentury reported that FDA regulatory moves reflect a steadying approach amid earlier controversy, with therapies from Moderna and Replimune emerging from disputes to receive approvals alongside Takeda’s nacrolepsy drug. The coverage frames recent approvals as outcomes of a contentious review cycle that is now settling into clearer decision-making. For industry, the key takeaway is how FDA is handling previously disputed submissions and advisory-material disputes—often setting precedent for what evidence packages and labeling approaches are likely to clear later scrutiny. Companies with programs in late-stage review will be watching for alignment in evidentiary expectations and post-approval commitments.